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OBJECTIVES Our purpose was to determine whether atrial fibrillation (AF) patients have alterations in
sarcoplasmic reticulum (SR) Ca21 regulatory proteins in the atrial myocardium.
BACKGROUND Clinically, AF is the most frequently encountered arrhythmia. Recent studies indicate that an
inability to maintain intracellular Ca21 homeostasis with a consequent increase in membrane-
triggered activity could be the primary initiating factor in some circumstances, and that
cytosolic Ca21 abnormalities are an important mediator of sustained AF.
METHODS We measured the maximum number of [3H]ryanodine binding sites (Bmax) and the
expression levels of ryanodine receptor (RyR) mRNA and calcium-adenosine triphosphatase
(Ca21-ATPase) mRNA in atrial myocardial tissue from 13 patients with AF due to mitral
valvular disease (MVD) and 9 patients with normal sinus rhythm (NSR).
RESULTS In AF patients, 1) Bmax was significantly lower in each atrium (0.21 6 0.03 pmol/mg [right],
0.16 6 0.04 pmol/mg [left]) than in the right atrium (0.26 6 0.08 pmol/mg) of NSR
patients; 2) Bmax was significantly lower in the left atrium than in the right atrium; 3) Bmax
in the left atrium was significantly lower at higher levels of pulmonary capillary wedge
pressure; 4) the expression level of RyR mRNA was significantly lower in both the left
(1.24 3 1022 6 1.28 3 1022) and right (1.70 3 1022 6 1.78 3 1022) atrium than in the
right atrium of NSR patients (6.11 3 1022 6 2.79 3 1022); and 5) the expression level of
Ca21-ATPase mRNA was significantly lower in both the left (5.67 3 1022 6 4.01 3 1022)
and right (7.71 3 1022 6 3.56 3 1022) atrium than in the right atrium (12.60 3 1022 6
3.92 3 1022) of NSR patients.
CONCLUSIONS These results provide the first direct evidence of abnormalities in the Ca21 regulatory proteins
of the atrial myocardium in chronic AF patients. Conceivably, such abnormalities may be
involved in the initiation and/or perpetuation of AF. (J Am Coll Cardiol 1999;34:255–63)
© 1999 by the American College of Cardiology
Atrial fibrillation (AF) is the most frequently encountered
arrhythmia in the clinical setting. Several epidemiological
observations suggest that AF is self-perpetuating; that is,
the tachyarrhythmia itself may produce electrophysiological
changes that exacerbate or maintain the problem (1–3). The
main electrophysiological mechanism underlying AF ap-
pears to be a progressive decrease in atrial refractoriness, a
phenomenon that has been termed “electrical remodeling”
(3). Although this phenomenon is thought to be of impor-
tance in the self-perpetuation of AF, the cellular and
molecular mechanisms that might initiate and/or maintain
AF remain unclear.
Ca21 is a ubiquitous intracellular signal mediator, and the
cardiac sarcoplasmic reticulum (SR) has the ability to
sequester Ca21. An action potential (AP) induces Ca21
release from the SR via Ca21-induced Ca21 release. Myo-
cardial contraction is triggered by Ca21 release from the SR
through a Ca21 release channel referred to as the ryanodine
receptor (RyR), and myocardial relaxation depends on
ATP-supported SR Ca21-ATPase (calcium-adenosine
triphosphatase), which mediates Ca21 uptake into the SR.
Moreover, Ca21, once released from the SR, interacts with
sarcolemmal binding sites to produce an inward current that
affects the repolarization of the AP. The notion that a
disordered regulation of cytosolic Ca21 plays a causal role in
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ventricular fibrillation is suggested by several studies of
ventricular fibrillation in vitro, which have shown intracel-
lular Ca21 overload (4–8). Furthermore, recent studies have
indicated that a failure of intracellular Ca21 homeostasis,
with a consequent increase in membrane-triggered activity
(9), could be the primary initiating factor in AF in some
circumstances. Increases in intracellular Ca21 concentration
have been shown to produce a negative feedback effect on
L-type Ca21 channel activity with a decrease in the plateau
phase of the AP (10).
Moreover, the finding of a blockade of electrical remod-
eling by verapamil and its enhancement by hypercalcemia
suggests that cytosolic Ca21 overload may be an important
mediator of AF (11). To judge from such evidence, there is
a possibility that alterations in SR Ca21 regulatory proteins,
which play an important role in the regulation of intracel-
lular Ca21, may occur in the atrial myocardium of patients
with chronic AF.
The purpose of our present study was to determine
whether patients with chronic AF have alterations in the SR
Ca21 regulatory proteins (RyR and Ca21-ATPase) in their
atrial tissue. We studied RyR binding and the expression
levels of RyR mRNA (messenger ribonucleic acid) and
Ca21-ATPase mRNA in the right and/or left atrium after
its removal during cardiac surgery from patients with AF
and from patients with normal sinus rhythm (NSR).
METHODS
Selection of patients. We examined right atrial tissue
(atrial appendage and/or atrial free wall) from 13 patients in
whom atrial fibrillation (AF) had been sustained for more
than six months; this tissue was obtained during cardiac
surgery for mitral valvular disease (MVD). Right atrial
tissue (atrial appendage) from nine patients with a normal
sinus rhythm (NSR), obtained during cardiac surgery for
coronary artery bypass, thoracic aortic aneurysm, or MVD,
was used as control material. We also examined left atrial
tissue (atrial free wall) obtained from 10 AF patients with
MVD. All the patients were evaluated by the Second
Department of Internal Medicine, Yamaguchi University
School of Medicine, and they underwent surgery at the
Yamaguchi University Hospital. Informed consent was
obtained from each patient. The protocols were in accord
with guidelines laid down by the Institutional Review
Board, Yamaguchi University Hospital. Demographic data,
including age, sex, diagnosis, and hemodynamic data, are
shown in Table 1. In addition to their usual medication, all
the patients received preoperative sedation and perioperative
anesthesia. Hemodynamic and echocardiographic data were
obtained by reviewing data from preoperative cardiac cath-
eterizations and echocardiograms.
Myocardial tissue samples. Right and/or left atrial tissues
were frozen immediately and stored at 280°C until needed.
They were used to prepare a crude homogenate for the assay
of ryanodine receptor binding and to produce RNA for
reverse transcription–polymerase chain reaction (RT-PCR)
amplification.
Atrial crude homogenate preparation. A crude homoge-
nate for the [3H]ryanodine binding assay was prepared as
previously described, with some modifications (12–14).
Atrial tissue (;100 mg) was homogenized twice for 20 s
each time, using a Brinkmann Polytron, in 20 mmol/liter
Tris-maleate containing 0.3 mol/liter sucrose, 0.1 mol/liter
KCl, 5 mg/liter leupeptin, and 0.1 mmol/liter phenylmeth-
ylsulfonyl fluoride (PMSF), at pH 7.0. The homogenate
Abbreviations and Acronyms
AF 5 atrial fibrillation
Ca21-ATPase 5 calcium-adenosine triphosphatase
mRNA 5 messenger ribonucleic acid
MVD 5 mitral valvular disease
NSR 5 normal sinus rhythm
RT-PCR 5 reverse transcription–polymerase chain
reaction
RyR 5 ryanodine receptor
SR 5 sarcoplasmic reticulum













1 IHD 64/M 66 8 15 11 38
2 IHD 63/M 63 3 14 9 41
3 IHD 67/M 55 4 12 8 31
4 IHD 60/M 64 3 11 5 43
5 TAA 74/M 68 – – – 41
6 TAA 71/F 63 – – – 43
7 TAA 72/M 72 2 14 4 36
8 TAA 67/M 62 2 14 4 34
9 MVD 65/F 65 0 14 7 43
NSR 5 normal sinus rhythm; EF 5 left ventricular ejection fraction; RAP 5 right atrial pressure; mPAP 5 mean pulmonary
arterial pressure; PCWP 5 pulmonary capillary wedge pressure; LAd 5 left atrial diameter; IHD 5 ischemic heart disease;
TAA 5 thoracic aortic aneurysm; MVD 5 mitral valvular disease.
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was filtered through two layers of cheesecloth. Protein
concentration was determined by the method of Lowry et al.
(15), using bovine serum albumin as standard. Aliquots of
homogenate were frozen in liquid nitrogen and stored at
280°C until used.
RNA preparation. Total cellular RNA was isolated from
each frozen tissue sample (;50 mg) by the method of acid
guanidinium thiocyanate/phenol/chloroform extraction
(16), then stored at 280°C.
Assay of [3H]ryanodine binding. [3H]Ryanodine-binding
assays were carried out according to previously described
methods (12–14). Briefly, crude homogenate (0.3 mg/ml)
was incubated for 90 min at 37°C in 25 mmol/liter imida-
zole (pH 7.4), 1.0 mol/liter KCl, 1.103 mmol/liter CaCl2,
and 0.95 mmol/liter EGTA (20 mmol/liter free Ca21), in
each case with a concentration of [3H]ryanodine from
within the range 0.6 to 20 nmol/liter. The reaction was
terminated by rapid filtration of 1 ml of the incubation
mixture through a glass fiber filter (Whatman GF/C,
Maidstone, United Kingdom) under reduced pressure. To
minimize the nonspecific binding component, each filter
was immediately washed with 5 ml of ice-cold buffer (25
mmol/liter imidazole, 1.0 mol/liter KCl, 1.103 mmol/liter
CaCl2, 0.95 mmol/liter EGTA, at pH 7.4) and removed
while under vacuum. After the addition of 5 ml of scintil-
lation fluid, the radioactivity was counted in a scintillation
counter (LSC-5100, Aloka, Tokyo, Japan). Nonspecific
binding was determined in the presence of 2 mmol/liter
unlabeled ryanodine.
Reverse transcription (RT) and polymerase chain reac-
tion (PCR) amplification (RT-PCR). The cDNA was
prepared using a Takara RNA PCR Kit (Takara, Tokyo,
Japan) in a buffer containing 10 mmol/liter Tris-HCl, pH
8.3, 50 mmol/liter KCl, 5 mmol/liter MgCl2, and 1 mmol/
liter each of dCTP, dGTP, dTTP, and dATP, with 20 U of
recombinant ribonuclease inhibitor, 2.5 mmol/liter random
9 mers, 1.3 mg of total RNA, 5 U of avian myeloblastosis
virus reverse transcriptase, all in a volume of 20 ml. This
reaction mixture was incubated for 10 min at 30°C followed
by 30 min at 42°C to initiate synthesis of cDNAs. Reverse
transcriptase was inactivated at 99°C for 5 min, and this
mixture was then used for the amplification of specific
cDNAs by PCR. The PCR was performed as follows: to 20
ml of the RT reaction mixture were added 2 ml of 0.1
mol/liter forward primer, 2 ml of 0.1 mol/liter reverse
primer, 8 ml of 10 3 amplification buffer (100 mmol/liter
Tris-HCl, pH 8.3, 500 mmol/liter KCl), 12 ml of 25
mmol/liter MgCl2, 55 ml of H2O, 0.5 ml of [a2
32P]dCTP
(Amersham), and 0.5 ml (2.5 U/100 ml) of Taq polymerase.
The primers for the amplification of the cardiac RyR,
Ca21-ATPase, and glyceraldehyde-3-phosphate dehydro-
genase (GAPDH) were designed from published sequences.
For RyR they were based on rabbit sequences (17): at
positions 1577–1597 (sense primer, 59-GGA AAT CCA
TTC TGA ATT CTC-39) and 2043–2064 (antisense
primer, 59-GCA GTC GTC ACA AAC GGC TCG
GTG-39) (predicted length of the PCR product, 487 bp).
For Ca21-ATPase they were based on human cardiac
sequences (18): at positions 2748 –2771 (sense primer, 59-
CGA AAA CCA GTC CTT GCT GAG GAT-39) and
2970 –2993 (antisense primer, 59-TAC TCC AGT ATT
GGC ATG CCG AGA-39) (predicted length of the PCR
product, 296 bp). For GAPDH they were based on human
sequences (19): at positions 102–125 (sense primer, 59-CTT
CAT TGA CCT CAA CTA CAT GGT-39) and 805– 828
(antisense primer, 59-CTC AGT GTA GCC CAG GAT
GCC CTT-39) (predicted length of the PCR product, 726
bp).
Next, 100 ml of reaction mixture was overlaid with 20 ml
mineral oil, and cycling was performed 22 times by means of
a thermal cycler (Perkin-Elmer/Cetus, San Diego, Califor-
nia) using the following parameters: denaturation at 94°C
for 1 min, annealing at 60°C for 1 min, extension at 72°C
for 2 min, followed by a final incubation at 72°C for 7 min.
RT-PCR cloning and sequencing of the cardiac ryano-
dine receptor cDNA. Heart total RNA was reverse-
transcribed into single-strand cDNA and amplified under
the same conditions as above. The amplified products were
separated on a 1% agarose gel (Doujin, Kumamoto, Japan),
then isolated from the gel and directly ligated into a pCRII
vector (Invitrogen, San Diego, California). Both strands of
the insert into the plasmid were completely sequenced by
the dideoxy chain termination method (20) using the
dsDNA Cycle Sequencing System (GIBCO BRL, Gaith-
ersburg, Maryland).
Quantitation of PCR products. The optimal number of
amplification cycles needed to allow quantitation of cardiac
RyR, Ca21-ATPase, and GAPDH gene PCR products was
determined. The PCR products for each cycle were sub-
jected to 5% polyacrylamide gel electrophoresis (PAGE)
and autoradiography, and the associated radioactivity was
measured using an imaging analyzer (model BAS-2000;
Fuji Photo Film, Tokyo, Japan). The optimal number of
cycles for cardiac RyR, Ca21-ATPase, and GAPDH was
found to be 22 in each case (21).
Assessment of expression of cardiac ryanodine receptor
and Ca21-ATPase mRNA. The relative radioactivity as-
sociated with cardiac RyR or Ca21-ATPase PCR products
in each sample was calculated by dividing the radioactivity
associated with the RyR or Ca21-ATPase PCR products by
the radioactivity associated with the GAPDH gene product
(internal control; amplified simultaneously). Each level of
RT-PCR product was the average of duplicate data. We
used GAPDH as an internal control because the densito-
metric scores for the mRNAs did not differ among the
groups of patients. Furthermore, this enzyme of the glyco-
lytic pathway is constitutively expressed in most tissues and
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is the most widely accepted internal control in the molecular
biology literature (22).
Statistical analysis. All data are presented as mean 6 SD.
Comparisons between data were performed by a two-way
analysis of variance (ANOVA) followed by the Scheffe´ test.
Differences were taken to be significant at p , 0.05.
RESULTS
Clinical characteristics and hemodynamic data. The pre-
operative hemodynamic and echocardiographic data for the
two groups are shown in Tables 1 and 2. The right atrial
pressure (RAP; 6.2 6 3.0 mm Hg), pulmonary capillary
wedge pressure (PCWP; 15.7 6 4.7 mm Hg), and mean
pulmonary arterial pressure (mPAP; 24.2 6 8.4 mm Hg) in
patients with AF due to MVD were significantly higher
than the corresponding values in patients with NSR (3.1 6
2.5, 6.9 6 2.7, 13.4 6 1.4 mm Hg, respectively, p , 0.05).
Moreover, the left atrial diameter (LAd; 62.8 6 12.5 mm)
measured by echocardiography in patients with AF due to
MVD was significantly larger (p , 0.05) than the atrial
diameter (38.9 6 4.4 mm) measured in patients with NSR.
The left ventricular ejection fraction was similar in the two
groups (AF vs. NSR, 59 6 9% vs. 64 6 5%).
Assay of [3H]ryanodine binding. In patients with AF due
to MVD, there was a significant depression in the maxi-
mum number of binding sites (Bmax) in each atrium
(0.21 6 0.03 pmol/mg in the right atrium, 0.16 6 0.04
pmol/mg in the left atrium) by comparison with the level in
the right atrium (0.26 6 0.08 pmol/mg) of patients with
NSR (Fig. 1). In patients with AF, the Bmax in the left
atrium was significantly lower than that in the right atrium.
In contrast, the dissociation constant (Kd) of [3H]ryanodine
Figure 1. Characteristics of [3H]ryanodine binding to atrial tissue in patients with either atrial fibrillation (AF) or normal sinus rhythm
(NSR). In patients with AF, there was a significant depression in the maximum number of binding sites (Bmax) in each atrium (by
comparison with the value for the right atrium in patients with NSR). The dissociation constant (Kd) did not differ significantly among
the three groups. R, right atrium; L, left atrium. Data are mean 6 SD.













1 MVD 69/F 72 9 25 18 84
2 MVD 50/F 52 7 42 23 50
3 MVD 47/M 54 6 34 23 56
4 MVD 63/F 72 9 22 12 75
5 MVD 64/M 61 8 30 21 49
6 MVD 68/F 67 2 33 15 54
7 MVD 55/F 54 4 11 10 66
8 MVD 66/F 64 3 18 10 59
9 MVD 68/M 43 1 18 12 52
10 MVD 63/F 55 9 22 19 58
11 MVD 62/M 64 9 22 19 58
12 MVD 73/F 55 9 20 14 62
13 MVD 47/F 48 5 19 15 64
AF 5 atrial fibrillation; EF 5 left ventricular ejection fraction; RAP 5 right atrial pressure; mPAP 5 mean pulmonary arterial
pressure; PCWP 5 pulmonary capillary wedge pressure; LAd 5 left atrial diameter; MVD 5 mitral valvular disease.
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binding did not differ significantly among the three groups
(Fig. 1).
Next, the Bmax data for AF patients were broken down
according to the patient’s PCWP, mPAP, or RAP. Figure
2 (i) shows the relationship between the Bmax for RyR in
the left atrium and PCWP. The Bmax was 0.19 6 0.01
pmol/mg in the group with the lower levels of PCWP
(#14 mm Hg) and 0.14 6 0.04 pmol/mg in the group with
the higher PCWP ($15 mm Hg), and there was a signif-
icant difference between the two groups. For mPAP (ii in
Fig. 2), the Bmax in the left atrium was 0.19 6 0.01
pmol/mg in the group with the lower levels (#19 mm Hg)
and 0.14 6 0.05 pmol/mg in the group with the higher
levels ($20 mm Hg). To judge from these values, Bmax
tended to be smaller, though not significantly (p 5 0.09),
at higher levels of mPAP. No correlation was found
between RAP and the Bmax for RyR in the right atrium
(iii in Fig. 2).
Analysis of expression levels of mRNA for the cardiac
ryanodine receptor and Ca21-ATPase. The expression
levels of the mRNAs encoding cardiac RyR and Ca21-
ATPase were examined, using total RNA extracted from
atrial tissues taken from patients with AF or NSR. Figure 3
shows the levels of these two mRNAs in patients with AF
or NSR, and representative mRNA levels for RyR and
Ca21-ATPase. The expression level of RyR mRNA in
homogenates prepared from the right (1.70 3 1022 6
1.78 3 1022) and the left (1.24 3 1022 6 1.28 3 1022)
atrium of patients with AF was significantly lower than that
Figure 2. Relation between the maximum number of [3H]ryanodine binding sites (Bmax) in the atrium of patients with atrial fibrillation
(AF) and magnitude of pulmonary capillary wedge pressure (PCWP) (i), mean pulmonary arterial pressure (mPAP) (ii), and right atrial
pressure (RAP) (iii). The Bmax for RyR was smaller at higher levels of PCWP. There was no significant difference between the Bmax
values obtained for the two levels of mPAP or the two levels of RAP. Data are mean 6 SD.
Figure 3. Expression levels of the mRNAs encoding cardiac RyR (A) and Ca21-ATPase (B) in the atrial tissue of patients with either
atrial fibrillation (AF) or normal sinus rhythm (NSR), and representative data showing the levels of the two mRNAs. In patients with AF,
there was a significant depression in the expression levels of RyR mRNA (A) and Ca21-ATPase mRNA (B) in each atrium (by comparison
with the levels in the right atrium of patients with NSR). R, right atrium; L, left atrium. Data are mean 6 SD.
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in the right atrium (6.11 3 1022 6 2.79 3 1022) of patients
with NSR (Fig. 3,A). The expression level of Ca21-ATPase
mRNA in the right (7.71 3 1022 6 3.56 3 1022) and the
left (5.67 3 1022 6 4.01 3 1022) atrium of patients with
AF was also significantly lower than that in the right atrium
(12.60 3 1022 6 3.92 3 1022) of patients with NSR (Fig.
3B). There were no significant differences in the expression
level of these two mRNAs between the right and left atrium
of patients with AF (Fig. 3A and B).
Next, the data for the expression levels of RyR mRNA
and Ca21-ATPase mRNA in the left atrium of patients
with AF were broken down according to the patient’s
PCWP and mPAP, and the expression levels of these two
mRNAs in the right atrium of patients with AF were
broken down according to their RAP. In fact, there was no
significant difference in the RyR mRNA expression levels
between groups with low or high values for any of these
pressure parameters (Fig. 4A-i to A-iii). Furthermore, there
were no significant differences in the Ca21-ATPase mRNA
expression levels between groups with low or high values for
any of the pressure parameters (Fig. 4B-i to B-iii).
DISCUSSION
The main findings of the present study were that in patients
with atrial fibrillation (AF) due to mitral valvular disease
(MVD): 1) there were significant decreases in the Bmax for
RyR and the expression levels of RyR mRNA and Ca21-
ATPase mRNA in both atria, and the Bmax for RyR was
smaller in the left atrium than in the right; and 2) the Bmax
in the left atrium was smaller at higher levels of PCWP.
Conversely, the expression levels of RyR mRNA and
Ca21-ATPase mRNA in the left atrium were not signifi-
cantly affected by the levels of PCWP or mPAP, and no
correlation was found between RAP and any of these
parameters in the right atrium. To our knowledge, although
there have been many investigations of sarcolemmal elec-
trophysiological characteristics (11,23–27), this is the first
investigation in which alterations in SR Ca21 regulatory
proteins (RyR and Ca21-ATPase) in atrial myocardial
tissue have been evaluated in patients with chronic AF due
to MVD. These alterations might act to sustain abnormal
intracellular Ca21 handling and changes in the electrophysi-
ologic properties of atrial tissue, and thus be responsible for
the maintenance of AF. However, such changes could also
be a consequence of AF. We will elaborate on this point
later in the Discussion.
Comparison between the right and left atrium in chronic
AF in terms of the Bmax for RyR, and the expression
levels of RyR mRNA and Ca21-ATPase mRNA. The
present study shows a decreased ryanodine binding to atrial
Figure 4. Relation between the expression level of RyR mRNA (A) or Ca21-ATPase mRNA (B) in the atrium of patients with atrial
fibrillation (AF) and magnitude of pulmonary capillary wedge pressure (PCWP) (A-i, B-i), mean pulmonary arterial pressure (mPAP)
(A-ii, B-ii), and right atrial pressure (RAP) (A-iii, B-iii). Data are mean 6 SD.
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tissue (implying a decreased RyR density) and decreased
expression levels of RyR mRNA and Ca21-ATPase mRNA
in both atria in MVD patients with AF (by comparison with
the values for patients with NSR). Interestingly, in our AF
patients the Bmax for RyR was smaller in the left atrium
than in the right, and the expression levels of the two
mRNAs tended to be lower in the left atrium than in the
right. We have previously reported a decrease in SR Ca21
release and uptake functions, as well as a decrease in the
number of RyR, and abnormal Ca21 handling in the
myocardium during the development of volume-overloaded
heart failure (28). On this basis, in MVD patients with AF,
direct mechanical overload of the left atrium might result in
abnormal Ca21 handling and in alterations in SR Ca21
regulatory proteins.
In contrast, Ausma et al. (29) reported that sustained AF
leads to marked structural changes in the atrium (such as
loss of myofibrils, accumulation of glycogen, changes in
mitochondrial shape and size, fragmentation of the SR, and
dispersion of nuclear chromatin), and these findings are
characteristics of intracellular Ca21 overload. While the
present paper was in preparation, Lai et al. (30) reported
that the mRNAs of the L-type Ca21 channel and of
Ca21-ATPase were downregulated in patients with AF;
such changes will further contribute to the shortening of
action potential duration, to cytosolic Ca21 overload, and
significantly to the perpetuation of AF. The observations of
Ausma et al. (29) and Lai et al. (30) indicate that AF itself
could cause a depression in the expression levels of Ca21
regulatory proteins. Thus, the results mentioned above
could be interpreted as suggesting that changes in the
expression levels of Ca21 regulatory proteins in patients
with MVD may cause AF, or be a consequence of AF, or
indeed be both a cause and a consequence in a self-
perpetuating process that leads to the establishment of
chronic AF.
Bmax for RyR, expression levels of RyR mRNA and
Ca21-ATPase mRNA and their correlation with clinical
hemodynamic parameters in chronic AF. The expression
levels of RyR mRNA and Ca21-ATPase mRNA in the left
atrium of chronic AF patients showed no significant corre-
lation with PCWP or mPAP. Moreover, no correlation was
found between RAP and the Bmax for RyR or the expres-
sion levels of RyR mRNA and Ca21-ATPase mRNA in the
right atrium of patients with AF. In patients with chronic
AF, these gene expression changes would not improve even
if normal cardiac hemodynamics could be maintained with
the aid of medication.
In addition, these results suggest that the sustained
decreases in the levels of gene expression were related to the
AF itself (rather than being mediated by the hemodynamic
deterioration). Our data is consistent with the very recent
study by Lai et al. (30), which reported that a downregula-
tion of genes for the L-type Ca21 channel and SR Ca21-
ATPase is a consequence of AF. However, in their study,
the level of the mRNA for RyR showed no significant
change in AF patients. We believe this inconsistency may be
related to the duration of AF and/or the different levels of
hemodynamic parameters. We examined patients in whom
chronic AF had persisted for more than six months, while
Lai et al. studied patients with chronic AF lasting for more
than three months. Moreover, the RAP, PCWP, and
mPAP in our patients with AF due to MVD were signifi-
cantly higher than the corresponding values in patients with
NSR. Interestingly, the Bmax for RyR in the left atrium in
chronic AF was smaller at higher levels of PCWP. This
result suggests that despite a markedly decreased Bmax for
RyR in the left atrium in chronic AF, the compensation
mechanism responding to changes in pressure may be
preserved at the level of protein expression, at least to some
extent.
We tried to investigate the possible correlation between
left atrial diameter (LAd) and the Bmax for RyR and the
expression levels of RyR mRNA and Ca21-ATPase mRNA
in the left atrium of patients with AF. In a report by Henry
et al. (31), the rate of AF was 3% when LAd was ,4.0 cm,
but it increased to 54% when LAd was .4.0 cm. This
suggests that there might be an LAd threshold for the
initiation and maintenance of AF. In our study, the values
of LAd for all patients with AF were .4.0 cm (Table 2).
This may be why we could find no correlation between the
expression level of the mRNAs for Ca21 regulatory proteins
and LAd (data not shown).
Alterations in SR Ca21 regulatory proteins and their
possible relation to the mechanisms causing chronic AF.
Some reports have described animal models that clearly
show the phenomenon of AF generating (or “begetting”)
further AF (23,24). In contrast to the baseline state, in
which there was prompt and spontaneous termination of
induced AF, animals subjected to chronic, rapid atrial rates
developed persistent AF. The mechanism underlying this
increase in AF duration appears to involve a progressive
decrease in atrial refractoriness, a phenomenon that has
been termed “electrical remodeling” (3). In addition to the
decreased refractoriness, factors such as atrial dilation,
depressed conduction, and increased heterogeneity either in
intra-atrial conduction or in the recovery of excitability are
all considered to be crucially important mechanisms leading
to the establishment of chronic AF (24). Although such
electrical remodeling is assumed to be important in the
self-perpetuation of AF, the mechanism underlying this
phenomenon is unknown. In the myocardium, the inward
Ca21 current is thought to be produced by Ca21 released
from the SR (via Ca21-induced Ca21 release), which then
interacts with sarcolemmal binding sites (32). In fact,
increases in intracellular Ca21 concentration have been
shown to produce a negative feedback effect on L-type Ca21
channel activity, with a consequent decrease in the plateau
phase of the action potential (10). This being so, the inward
Ca21 current might be controlled in a complex way by a
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variety of factors, including the L-type Ca21 current-trigger
for Ca21 release, the Ca21 load in the SR, SR function, and
the physical proximity between elements of the system
(L-type Ca21 channels, RyRs, Ca21-ATPase, and so forth).
Of the above factors, the one we should like to focus on
at present is the SR Ca21 regulatory proteins. Interestingly,
several in vitro studies of ventricular fibrillation have shown
intracellular Ca21 overload (4–8). As mentioned above, we
have previously reported a decrease in SR Ca21 release and
uptake functions, as well as a decrease in the number of
RyR, and an abnormal Ca21 handling in the myocardium
during the development of volume-overloaded heart failure
(28). With regard to the establishment of AF, the following
is a possible scenario. The decreased expression level of
Ca21-ATPase mRNA in patients with MVD shown in our
study could cause a reduced re-uptake of intracellular Ca21,
and thus result in intracellular Ca21 overload in the atrium.
In addition to the decreased expression level of Ca21-
ATPase mRNA, a decrease in RyR density and a decrease
in the expression level of RyR mRNA could both contribute
to a failure of Ca21 homeostasis. Consequent abnormalities
in the SR Ca21 regulatory proteins may cause a further
intracellular Ca21 abnormality leading to additional damage
to the SR Ca21 regulatory proteins. Such self-perpetuating
changes could, in part, contribute to the maintenance of AF
as AF begets further AF. However, although this seems an
attractive idea to us, direct evidence of changes in Ca21
handling during the initiation or maintenance of AF is still
lacking, and further studies will be needed to investigate the
actual changes occurring in intracellular Ca21 transients in
atrial myocytes during the development of chronic AF.
Study limitations. In our study, we used only the right, not
the left, atrium of patients with NSR as a control. We could
not obtain left atrial tissue from surgical patients except for
those undergoing a left atrial plication procedure for a giant
left atrium. In those patients with NSR used as controls, the
hemodynamic data (obtained by reviewing the results of
preoperative cardiac catheterization and echocardiography)
was normal, and we decided that there was no abnormal
overload in either atrium and considered them to be under
the same conditions. Moreover, because of the small num-
ber of MVD patients with NSR, we could not compare data
from MVD patients with AF and MVD patients with NSR.
However, we could determine the Bmax for RyR and the
expression levels of RyR mRNA and Ca21-ATPase mRNA
in both atria in the one MVD patient with NSR (Table 1,
patient no. 9). Interestingly, in this patient the Bmax for
RyR and the expression levels of RyR mRNA and Ca21-
ATPase mRNA in both atria were larger than the mean
values for those MVD patients with chronic AF (data not
shown). This patient had normal hemodynamic data except
for a slightly enlarged left atrium (diameter was 43 mm).
This result suggests that markedly increased chamber size
and intra-atrial pressure may be important factors for the
initiation of chronic AF.
Because the amount of atrial tissue obtained was small,
we used crude membrane preparations for the RyR binding
assay, as in a previous study using small samples (33).
Although, in a study of the present type, the question of
tissue normalization is an important point, we could not
accurately assess at the SR vesicle content and we could not
carry out a histopathological study on identical samples.
We have speculated that abnormalities in SR Ca21
regulatory proteins may contribute to a sustaining of intra-
cellular Ca21 overload; however, we did not directly mea-
sure intracellular Ca21 transients. Clearly, an examination
of Ca21 transients and SR Ca21-release and -uptake func-
tions in human atrial myocytes from patients with chronic
AF would be of great interest.
Conclusions. Recently, several investigators have reported
electrophysiological abnormalities of the sarcolemma and
discussed intracellular Ca21 overload as a possible cause of
the initiation and/or maintenance of AF. However, there is
a lack of direct evidence of either abnormal intracellular
Ca21 handling or abnormalities in the modulators of the
intracellular Ca21 concentration. In this study, we report
direct evidence of abnormalities in SR Ca21 regulatory
proteins in the atrium of patients with chronic AF, and we
suggest that these changes might be a cause and/or result of
AF, perhaps forming part of a self-perpetuating process by
which AF begets further AF, leading to the establishment
of a chronic condition.
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